We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
Read MoreHide Full Article
Key Takeaways
Precigen is expected to report Q3 2026 sales of $75.4 million and earnings of 9 cents per share.
Papzimeos sales momentum remains key, after it more than doubled sequentially in Q2 2026.
PGEN will provide updates on PRGN-2009, its investigational AdenoVerse immunotherapy for HPV-driven cancers.
Precigen (PGEN - Free Report) is scheduled to report third-quarter 2026 earnings on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $75.4 million, while the same for earnings is pinned at 9 cents per share.
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence PGEN's Q3 Results
Precigen’s revenues are likely to have been driven by strong sales of its sole marketed drug, Papzimeos (zopapogene imadenovec-drba), during the third quarter. Papzimeos is an FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug has witnessed strong commercial momentum since its approval and launch.
Product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026. It remains to be seen whether the same trend continued in the to-be-reported quarter.
A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe. A potential approval in Europe could further boost the drug’s sales and drive revenues. Management can provide an update on the timeline for the approval on the upcoming investor call.
Year to date, shares of Precigen have surged 66.1% compared with the industry’s increase of 11.3%.
Image Source: Zacks Investment Research
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in mid-stage studies for HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
Investors will be keen to get more clinical and regulatory updates on the company's pipeline progress on the upcoming call.
Potential Competition Ails PGEN’s Stock
Last week, the FDA granted accelerated approval to Inovio Pharmaceuticals’ (INO - Free Report) Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously known as INO-3107, to reduce the frequency of surgery in adults with RRP.
The FDA approval on Oct. 30 reportedly weighed on investor sentiment toward Precigen’s Papzimeos, sending its shares plunging around 20% as investors assessed the potential competitive threat from INO’s Voceryq.
Inovio expects to begin making Voceryq available for ordering and shipment in approximately 60 days, with a full commercial launch planned for the first quarter of 2027.
PGEN's Earnings Surprise History
Precigen has a mixed earnings-surprise history. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 108.96%. In the last reported quarter, PGEN posted an earnings surprise of 350.00%.
Our proven model does not conclusively predict an earnings beat for Precigen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Precigen’s Earnings ESP is -7.69% as the Most Accurate Estimate stands at 8 cents per share, lower than the Zacks Consensus Estimate of 9 cents.
Here are two drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
Amneal’s stock has surged 70.7% so far this year. AMRX beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen 28.9% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter results on Nov. 3.
View the Zacks #1 Rank List
Image: Bigstock
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
Key Takeaways
Precigen (PGEN - Free Report) is scheduled to report third-quarter 2026 earnings on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $75.4 million, while the same for earnings is pinned at 9 cents per share.
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence PGEN's Q3 Results
Precigen’s revenues are likely to have been driven by strong sales of its sole marketed drug, Papzimeos (zopapogene imadenovec-drba), during the third quarter. Papzimeos is an FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug has witnessed strong commercial momentum since its approval and launch.
Product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026. It remains to be seen whether the same trend continued in the to-be-reported quarter.
A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe. A potential approval in Europe could further boost the drug’s sales and drive revenues. Management can provide an update on the timeline for the approval on the upcoming investor call.
Year to date, shares of Precigen have surged 66.1% compared with the industry’s increase of 11.3%.
Image Source: Zacks Investment Research
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in mid-stage studies for HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
Investors will be keen to get more clinical and regulatory updates on the company's pipeline progress on the upcoming call.
Potential Competition Ails PGEN’s Stock
Last week, the FDA granted accelerated approval to Inovio Pharmaceuticals’ (INO - Free Report) Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously known as INO-3107, to reduce the frequency of surgery in adults with RRP.
The FDA approval on Oct. 30 reportedly weighed on investor sentiment toward Precigen’s Papzimeos, sending its shares plunging around 20% as investors assessed the potential competitive threat from INO’s Voceryq.
Inovio expects to begin making Voceryq available for ordering and shipment in approximately 60 days, with a full commercial launch planned for the first quarter of 2027.
PGEN's Earnings Surprise History
Precigen has a mixed earnings-surprise history. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 108.96%. In the last reported quarter, PGEN posted an earnings surprise of 350.00%.
Precigen, Inc. Price and EPS Surprise
Precigen, Inc. price-eps-surprise | Precigen, Inc. Quote
Earnings Whispers for PGEN
Our proven model does not conclusively predict an earnings beat for Precigen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Precigen’s Earnings ESP is -7.69% as the Most Accurate Estimate stands at 8 cents per share, lower than the Zacks Consensus Estimate of 9 cents.
Zacks Rank: PGEN has a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are two drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2.
Amneal’s stock has surged 70.7% so far this year. AMRX beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter results on Nov. 3.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen 28.9% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter results on Nov. 3.